Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Incyte Corp (NQ: INCY ) 67.48 -0.58 (-0.84%) Streaming Delayed Price Updated: 3:25 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 761,859 Open 67.68 Bid (Size) 67.47 (7) Ask (Size) 67.50 (3) Prev. Close 68.06 Today's Range 66.26 - 67.82 52wk Range 50.27 - 70.36 Shares Outstanding 222,430,635 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Assessing Incyte: Insights From 11 Financial Analysts October 01, 2024 Via Benzinga Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate September 30, 2024 Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... Via Benzinga Exposures Product Safety Performance YTD +3.11% +3.11% 1 Month +1.77% +1.77% 3 Month +14.34% +14.34% 6 Month +20.88% +20.88% 1 Year +16.23% +16.23% More News Read More Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress September 25, 2024 From Incyte Via Business Wire Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets September 18, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) September 03, 2024 Via Benzinga Analyst Expectations For Incyte's Future August 15, 2024 Via Benzinga Analyst Ratings For Incyte July 26, 2024 Via Benzinga Looking for growth without the hefty price tag? Consider NASDAQ:INCY. July 22, 2024 Via Chartmill Wall Street Lower Ahead Of Interest Rate Move September 18, 2024 Via Talk Markets Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers September 16, 2024 Via Investor's Business Daily Topics Stocks Exposures US Equities Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer September 14, 2024 From Incyte Via Business Wire Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium September 14, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 09, 2024 From Incyte Via Business Wire Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 August 21, 2024 From Incyte Via Business Wire Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study August 16, 2024 Via Benzinga Exposures Product Safety Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma August 15, 2024 From Incyte Via Business Wire FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication August 15, 2024 Via Benzinga Exposures Product Safety Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) August 14, 2024 From Incyte and Syndax Pharmaceuticals Via Business Wire Incyte to Present at Upcoming Investor Conferences August 13, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 07, 2024 From Incyte Via Business Wire After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial July 31, 2024 Via Benzinga Topics Death Exposures Death Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance July 30, 2024 Via Benzinga Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs July 30, 2024 From Incyte Via Business Wire NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. July 10, 2024 Via Chartmill S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday? July 09, 2024 Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
